Epigenetic Mechanisms beyond Tumour–Stroma Crosstalk
Abstract
:Simple Summary
Abstract
1. Introduction
2. Tumour–Stroma Crosstalk Mediated by Epigenetic Mechanisms
2.1. Breast Cancer
2.2. Ovarian Cancer
2.3. Colorectal Cancer
2.4. Pancreatic Cancer
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Audia, J.E.; Campbell, R.M. Histone Modifications and Cancer. Cold Spring Harb. Perspect. Biol. 2016, 8, a019521. [Google Scholar] [CrossRef]
- Jones, P.A.; Ohtani, H.; Chakravarthy, A.; De Carvalho, D.D. Epigenetic therapy in immune-oncology. Nat. Rev. Cancer 2019, 19, 151–161. [Google Scholar] [CrossRef] [PubMed]
- Toh, T.B.; Lim, J.J.; Chow, E.K. Epigenetics in cancer stem cells. Mol. Cancer 2017, 16, 29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gagliano, T.; Brancolini, C. Targeting histone deacetylases for combination therapies in neuroendocrine tumors. Cancer Gene Ther. 2020, in press. [Google Scholar] [CrossRef]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [Green Version]
- Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 2016, 16, 582–598. [Google Scholar] [CrossRef]
- Fane, M.; Weeraratna, A.T. How the ageing microenvironment influences tumour progression. Nat. Rev. Cancer 2020, 20, 89–106. [Google Scholar] [CrossRef] [PubMed]
- Thomas, D.; Radhakrishnan, P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol. Cancer 2019, 18, 14. [Google Scholar] [CrossRef] [PubMed]
- Woolston, C. Breast cancer. Nature 2015, 527, S101. [Google Scholar] [CrossRef]
- Bauer, K.R.; Brown, M.; Cress, R.D.; Parise, C.A.; Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer 2007, 109, 1721–1728. [Google Scholar] [CrossRef] [PubMed]
- Ditsiou, A.; Cilibrasi, C.; Simigdala, N.; Papakyriakou, A.; Milton-Harris, L.; Vella, V.; Nettleship, J.E.; Lo, J.H.; Soni, S.; Smbatyan, G.; et al. The structure-function relationship of oncogenic LMTK3. Sci. Adv. 2020, 6, eabc3099. [Google Scholar] [CrossRef]
- Karsli-Ceppioglu, S.; Dagdemir, A.; Judes, G.; Ngollo, M.; Penault-Llorca, F.; Pajon, A.; Bignon, Y.J.; Bernard-Gallon, D. Epigenetic mechanisms of breast cancer: An update of the current knowledge. Epigenomics 2014, 6, 651–664. [Google Scholar] [CrossRef] [PubMed]
- Bertucci, F.; Ng, C.K.Y.; Patsouris, A.; Droin, N.; Piscuoglio, S.; Carbuccia, N.; Soria, J.C.; Dien, A.T.; Adnani, Y.; Kamal, M.; et al. Genomic characterization of metastatic breast cancers. Nature 2019, 569, 560–564, Erratum in 2019, 572, E7. [Google Scholar] [CrossRef] [PubMed]
- Ursini-Siegel, J.; Siegel, P.M. The influence of the pre-metastatic niche on breast cancer metastasis. Cancer Lett. 2016, 380, 281–288. [Google Scholar] [CrossRef] [PubMed]
- Bartoschek, M.; Oskolkov, N.; Bocci, M.; Lövrot, J.; Larsson, C.; Sommarin, M.; Madsen, C.D.; Lindgren, D.; Pekar, G.; Karlsson, G.; et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat. Commun. 2018, 9, 5150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tang, Q.; Hann, S.S. HOTAIR: An Oncogenic Long Non-Coding RNA in Human Cancer. Cell Physiol. Biochem. 2018, 47, 893–913. [Google Scholar] [CrossRef] [PubMed]
- Ren, Y.; Jia, H.H.; Xu, Y.Q.; Zhou, X.; Zhao, X.H.; Wang, Y.F.; Song, X.; Zhu, Z.Y.; Sun, T.; Dou, Y.; et al. Paracrine and epigenetic control of CAF-induced metastasis: The role of HOTAIR stimulated by TGF-ß1 secretion. Mol. Cancer 2018, 17, 5. [Google Scholar] [CrossRef]
- Clocchiatti, A.; Di Giorgio, E.; Viviani, G.; Streuli, C.; Sgorbissa, A.; Picco, R.; Cutano, V.; Brancolini, C. The MEF2-HDAC axis controls proliferation of mammary epithelial cells and acini formation in vitro. J. Cell Sci. 2015, 128, 3961–3976. [Google Scholar] [CrossRef] [Green Version]
- Caslini, C.; Hong, S.; Ban, Y.J.; Chen, X.S.; Ince, T.A. HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells. Oncogene 2019, 38, 6599–6614. [Google Scholar] [CrossRef] [Green Version]
- Cutano, V.; Di Giorgio, E.; Minisini, M.; Picco, R.; Dalla, E.; Brancolini, C. HDAC7-mediated control of tumour microenvironment maintains proliferative and stemness competence of human mammary epithelial cells. Mol. Oncol. 2019, 13, 1651–1668. [Google Scholar] [CrossRef] [Green Version]
- Clocchiatti, A.; Di Giorgio, E.; Ingrao, S.; Meyer-Almes, F.J.; Tripodo, C.; Brancolini, C. Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER+ breast tumors. FASEB J. 2013, 27, 942–954. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gagliano, T.; Shah, K.; Gargani, S.; Lao, L.; Alsaleem, M.; Chen, J.; Ntafis, V.; Huang, P.; Ditsiou, A.; Vella, V.; et al. PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression. J. Clin. Investig. 2020, 130, 3188–3204. [Google Scholar] [CrossRef]
- Gabrilovich, D.I. Myeloid-Derived Suppressor Cells. Cancer Immunol. Res. 2017, 5, 3–8. [Google Scholar] [CrossRef] [Green Version]
- Lu, Z.; Zou, J.; Li, S.; Topper, M.J.; Tao, Y.; Zhang, H.; Jiao, X.; Xie, W.; Kong, X.; Vaz, M.; et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature 2020, 579, 284–290. [Google Scholar] [CrossRef] [PubMed]
- Prompsy, P.; Kirchmeier, P.; Marsolier, J.; Deloger, M.; Servant, N.; Vallot, C. Interactive analysis of single-cell epigenomic landscapes with ChromSCape. Nat. Commun. 2020, 11, 5702. [Google Scholar] [CrossRef]
- Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 2010, 177, 1053–1064. [Google Scholar] [CrossRef]
- Hennessy, B.T.; Coleman, R.L.; Markman, M. Ovarian cancer. Lancet 2009, 374, 1371–1382. [Google Scholar] [CrossRef]
- Nitecki, R.; Diver, E.J.; Kamdar, M.M.; Boruta, D.M., 2nd; Del Carmen, M.C.; Clark, R.M.; Goodman, A.; Schorge, J.O.; Growdon, W.B. Patterns of palliative care referral in ovarian cancer: A single institution 5 year retrospective analysis. Gynecol. Oncol. 2018, 148, 521–526. [Google Scholar] [CrossRef] [PubMed]
- Yokoi, A.; Yoshioka, Y.; Yamamoto, Y.; Ishikawa, M.; Ikeda, S.I.; Kato, T.; Kiyono, T.; Takeshita, F.; Kajiyama, H.; Kikkawa, F.; et al. Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. Nat. Commun. 2017, 8, 14470. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tothill, R.; Tinker, A.; George, J.; Brown, R.; Fox, S.; Lade, S.; Johnson, D.; Trivett, M.; Etemadmoghadam, D.; Locandro, B.; et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 2008, 14, 5198–5208. [Google Scholar] [CrossRef] [Green Version]
- Karlan, B.; Dering, J.; Walsh, C.; Orsulic, S.; Lester, J.; Anderson, L.; Ginther, C.; Fejzo, M.; Slamon, D. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol. Oncol. 2014, 132, 334–342. [Google Scholar] [CrossRef]
- Lau, T.; Chan, L.; Wong, E.; Hui, C.; Sneddon, K.; Cheung, T.; Yim, S.; Lee, J.; Yeung, C.; Chung, T.; et al. A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFα-TGFα-EGFR. Oncogene 2017, 36, 3576–3587. [Google Scholar] [CrossRef] [PubMed]
- McLean, K.; Gong, Y.; Choi, Y.; Deng, N.; Yang, K.; Bai, S.; Cabrera, L.; Keller, E.; McCauley, L.; Cho, K.; et al. Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J. Clin. Investig. 2011, 121, 3206–3219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.; Keating, A.; Prockop, D.J.; Horwitz, E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8, 315–317. [Google Scholar] [CrossRef]
- Verardo, R.; Piazza, S.; Klaric, E.; Ciani, Y.; Bussadori, G.; Marzinotto, S.; Mariuzzi, L.; Cesselli, D.; Beltrami, A.; Mano, M.; et al. Specific mesothelial signature marks the heterogeneity of mesenchymal stem cells from high-grade serous ovarian cancer. Stem. Cells 2014, 32, 2998–3011. [Google Scholar] [CrossRef]
- Coffman, L.; Choi, Y.; McLean, K.; Allen, B.; di Magliano, M.; Buckanovich, R.J. Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget 2016, 7, 6916–6932. [Google Scholar] [CrossRef] [Green Version]
- Fan, H.; Atiya, H.; Wang, Y.; Pisanic, T.; Wang, T.; Shih, I.; Foy, K.; Frisbie, L.; Buckanovich, R.; Chomiak, A.; et al. Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis. Cell Rep. 2020, 33, 108473. [Google Scholar] [CrossRef]
- Mármol, I.; Sánchez-de-Diego, C.; Pradilla Dieste, A.; Cerrada, E.; Rodriguez Yoldi, M.J. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int. J. Mol. Sci. 2017, 18, 197. [Google Scholar] [CrossRef] [Green Version]
- Vermeulen, L.; De Sousa, E.; Melo, F.; van der Heijden, M.; Cameron, K.; de Jong, J.; Borovski, T.; Tuynman, J.; Todaro, M.; Merz, C.; et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12, 468–476. [Google Scholar] [CrossRef] [PubMed]
- Agrawal, K.; Das, V.; Táborská, N.; Gurský, J.; Džubák, P.; Hajdúch, M. Differential Regulation of Methylation-Regulating Enzymes by Senescent Stromal Cells Drives Colorectal Cancer Cell Response to DNA-Demethylating Epi-Drugs. Stem. Cells Int. 2018, 2018, 6013728. [Google Scholar] [CrossRef] [Green Version]
- Takeda, S.; Shigeyasu, K.; Okugawa, Y.; Yoshida, K.; Mori, Y.; Yano, S.; Noma, K.; Umeda, Y.; Kondo, Y.; Kishimoto, H.; et al. Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer. Cancer Lett. 2019, 444, 127–135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, J.; Bhasin, S.; Bielenberg, D.; Sukhatme, V.P.; Bhasin, M.; Huang, S.; Kieran, M.W.; Panigrahy, D. Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. FASEB J. 2019, 33, 114–125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hao, C.; Cui, Y.; Owen, S.; Li, W.; Cheng, S.; Jiang, W.G. Human osteopontin: Potential clinical applications in cancer (Review). Int. J. Mol. Med. 2017, 39, 1327–1337. [Google Scholar] [CrossRef] [Green Version]
- Chang, S.; Huang, J.; Niu, H.; Wang, J.; Si, Y.; Bai, Z.; Cheng, S.; Ding, W. Epigenetic regulation of osteopontin splicing isoform c defines its role as a microenvironmental factor to promote the survival of colon cancer cells from 5-FU treatment. Cancer Cell Int. 2020, 20, 452. [Google Scholar] [CrossRef]
- Sasidharan Nair, V.; Saleh, R.; Toor, S.; Alajez, N.; Elkord, E. Transcriptomic Analyses of Myeloid-Derived Suppressor Cell Subsets in the Circulation of Colorectal Cancer Patients. Front. Oncol. 2020, 10, 1530. [Google Scholar] [CrossRef]
- Tran, T.; Hanse, E.; Habowski, A.; Li, H.; Gabra, M.B.I.; Yang, Y.; Lowman, X.; Ooi, A.; Liao, S.; Edwards, R.; et al. α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer. Nat. Cancer 2020, 1, 345–358. [Google Scholar] [CrossRef] [PubMed]
- Philip, M.; Fairchild, L.; Sun, L.; Horste, E.; Camara, S.; Shakiba, M.; Scott, A.; Viale, A.; Lauer, P.; Merghoub, T.; et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 2017, 545, 452–456. [Google Scholar] [CrossRef] [PubMed]
- Sen, D.; Kaminski, J.; Barnitz, R.; Kurachi, M.; Gerdemann, U.; Yates, K.; Tsao, H.; Godec, J.; LaFleur, M.; Brown, F.; et al. The epigenetic landscape of T cell exhaustion. Science 2016, 354, 1165–1169. [Google Scholar] [CrossRef] [Green Version]
- Bian, Y.; Li, W.; Kremer, D.; Sajjakulnukit, P.; Li, S.; Crespo, J.; Nwosu, Z.; Zhang, L.; Czerwonka, A.; Pawłowska, A.; et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature 2020, 585, 277–282. [Google Scholar] [CrossRef]
- Shah, V.; Sheppard, B.; Sears, R.; Alani, A.W. Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer. Cancer Lett. 2020, 492, 63–70. [Google Scholar] [CrossRef]
- Kommalapati, A.; Tella, S.; Goyal, G.; Ma, W.; Mahipal, A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers 2018, 10, 24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zaghdoudi, S.; Decaup, E.; Belhabib, I.; Samain, R.; Cassant-Sourdy, S.; Rochotte, J.; Brunel, A.; Schlaepfer, D.; Cros, J.; Neuzillet, C.; et al. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. EMBO Mol. Med. 2020, 12, e12010. [Google Scholar] [CrossRef]
- Schnittert, J.; Bansal, R.; Mardhian, D.; van Baarlen, J.; Östman, A.; Prakash, J. Integrin α11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer. FASEB J. 2019, 33, 6609–6621. [Google Scholar] [CrossRef]
- Cao, C.; Wang, Q.; Li, Q.; Zhao, Q.; Wang, J.; Liu, Y. Development and Preliminary Clinical Application of Circulating Tumor Cell Detection System for Prostate Cancer. J. Biomed. Nanotechnol. 2019, 15, 612–620. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Chen, Z.; Xu, J.; Cao, X.; Chen, Q.; Liu, X.; Xu, Z.D. Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci. 2010, 101, 80–86. [Google Scholar] [CrossRef] [PubMed]
- Wei, L.; Ye, H.; Li, G.; Lu, Y.; Zhou, Q.; Zheng, S.; Lin, Q.; Liu, Y.; Li, Z.; Chen, R. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Cell Death Dis. 2018, 9, 1065. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.; Hu, L.; Qin, W.; Yang, Q.; Chen, D.; Li, Q.; Zhou, K.; Huang, P.; Xu, C.; Li, J.; et al. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Nat. Commun. 2021, 12, 174. [Google Scholar] [CrossRef] [PubMed]
- Leal, A.; Liu, P.; Krieger-Burke, T.; Ruggeri, B.; Liby, K.T. The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer. Cancers 2020, 13, 96. [Google Scholar] [CrossRef] [PubMed]
- Vonderheide, R.; Bear, A.S. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer. Front. Immunol. 2020, 11, 605619. [Google Scholar] [CrossRef]
- Li, J.; Yuan, S.; Norgard, R.; Yan, F.; Sun, Y.; Kim, I.; Merrell, A.; Sela, Y.; Jiang, Y.; Bhanu, N.; et al. Epigenetic and transcriptional control of the epidermal growth factor receptor (EGFR) regulates the tumor immune microenvironment in pancreatic cancer. Cancer Discov. 2020, in press. [Google Scholar] [CrossRef] [PubMed]
- Ying, H.; Dey, P.; Yao, W.; Kimmelman, A.; Draetta, G.; Maitra, A.; DePinho, R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016, 30, 355–385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, D.; Xue, J.; Lito, P. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell 2020, 183, 850–859. [Google Scholar] [CrossRef] [PubMed]
- Papke, B.; Der, C.J. Drugging RAS: Know the enemy. Science 2017, 355, 1158–1163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garrido-Laguna, I.; Hidalgo, M. Pancreatic cancer: From state-of-the-art treatments to promising novel therapies. Nat. Rev. Clin. Oncol. 2015, 12, 319–334. [Google Scholar] [CrossRef]
- Hou, P.; Kapoor, A.; Zhang, Q.; Li, J.; Wu, C.; Li, J.; Lan, Z.; Tang, M.; Ma, X.; Ackroyd, J.; et al. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discov. 2020, 10, 1058–1077. [Google Scholar] [CrossRef]
- Hass, R.; von der Ohe, J.; Ungefroren, H. The Intimate Relationship Among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to Be Exploited for Therapeutic Purposes. Cancers 2020, 12, 3674. [Google Scholar] [CrossRef]
- Pallasch, F.; Schumacher, U. Angiotensin Inhibition, TGF-β and EMT in Cancer. Cancers 2020, 12, 2785. [Google Scholar] [CrossRef]
- Valletta, S.; Thomas, A.; Meng, Y.; Ren, X.; Drissen, R.; Sengül, H.; Di Genua, C.; Nerlov, C. Micro-environmental sensing by bone marrow stroma identifies IL-6 and TGFβ1 as regulators of hematopoietic ageing. Nat. Commun. 2020, 11, 4075. [Google Scholar] [CrossRef]
- Zhu, Z.; Achreja, A.; Meurs, N.; Animasahun, O.; Owen, S.; Mittal, A.; Parikh, P.; Lo, T.; Franco-Barraza, J.; Shi, J.; et al. Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Nat. Metab. 2020, 2, 775–792. [Google Scholar] [CrossRef] [PubMed]
- Chen, X.; Song, E. Turning foes to friends: Targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 2019, 18, 99–115. [Google Scholar] [CrossRef]
- Gabrilovich, D.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9, 162–174. [Google Scholar] [CrossRef] [PubMed]
TME Componet | Molecules Involved | Epigenetic Mechanism/Modification | Cancer Types |
---|---|---|---|
Fibroblasts | TGF-β | HOTAIR | Breast Cancer [16] |
ADAR | Colorectal Cancer [41] | ||
SDF-1 | SATB-1 | Pancreatic Cancer [56] | |
TGF-α | Methylation | Ovarian Cancer [32] | |
Immune cells | methionine | Methylation/SAM | Colorectal Cancer [49] |
KDM3A | Pancreatic Cancer [60] | ||
TGF-β | HDAC5 | Pancreatic Cancer [65] | |
MSC | EZH2/WT1 | Ovarian Cancer [37] | |
MDSCs | Acetylation | Colorectal Cancer [44] | |
Metabolic microenviroment | glutamine | Methylation | Colorectal Cancer [47] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gagliano, T.; Brancolini, C. Epigenetic Mechanisms beyond Tumour–Stroma Crosstalk. Cancers 2021, 13, 914. https://doi.org/10.3390/cancers13040914
Gagliano T, Brancolini C. Epigenetic Mechanisms beyond Tumour–Stroma Crosstalk. Cancers. 2021; 13(4):914. https://doi.org/10.3390/cancers13040914
Chicago/Turabian StyleGagliano, Teresa, and Claudio Brancolini. 2021. "Epigenetic Mechanisms beyond Tumour–Stroma Crosstalk" Cancers 13, no. 4: 914. https://doi.org/10.3390/cancers13040914